CanSino Biologics CEO on earnings, business outlook, and international partnerships

featured-image

Yu Xuefeng, CEO of Chinese vaccine company CanSino Biologics, says the company remains on-track to breakeven in 2025, and remains committed to expanding into the global market. He also says the impact from US-China trade tensions for the company remains on the margins.

Monday - Friday, 10:00 - 11:00 SIN/HK | 0400 - 05:00 CET.